Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAdministrative/Operational PolicyHumana HMO D‑SNP Michigan Prior Auth Policy Update…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHumanaPolicy N/A

    Humana HMO D-SNP Michigan prior authorization and notification list (PAL)

    Customize your policy alerts

    Sign up for all Humana policy alerts

    Know when Humana releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists medications and services that require prior authorization or notification for Humana Dual Integrated HMO D-SNP members in Michigan and describes how providers should request prior authorization, required information, and related operational notes.

    Policy Summary
    PayerHumana
    PolicyHumana HMO D-SNP Michigan prior authorization and notification list (PAL)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionInitiate prior authorization via CoverMyMeds, phone at 866-461-7273 (TTY: 711) Mon–Fri 8 a.m.–11 p.m. ET, or fax to 888-447-3430 and include required patient identifiers, HCPCS/diagnosis codes, and provider TIN/NPI.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    90+medication entries shown (partial)
    3ways to initiate PA
    90 daysactive treatment exemption
    NDC requiredNDC billing requirement
    Transplant reviewtransplant review contact

    Medications and Coverage Rules Requiring Prior Authorization or Notification

    Prior authorization and coverage rules

    Covered when the following operational rules apply:

    Medications and services listed require prior authorization before being provided or administered for Humana HMO D-SNP Michigan members.
    Urgent or emergent services do not require prior authorization.

    See document: urgent/emergent services exempt from PA.

    Investigational or experimental procedures and devices are usually not covered; consult the member's Evidence of Coverage or Humana for confirmation.
    Step therapy may apply for certain Medicare Part B medications; review Humana's Part B Step Therapy Preferred Drug List for details and cross‑benefit strategies.
    Humana will not require prior authorization for active courses of treatment that began prior to a member's enrollment during the first 90 days of new member enrollment.
    Policy Summary
    PayerHumana
    PolicyHumana HMO D-SNP Michigan prior authorization and notification list (PAL)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionInitiate prior authorization via CoverMyMeds, phone at 866-461-7273 (TTY: 711) Mon–Fri 8 a.m.–11 p.m. ET, or fax to 888-447-3430 and include required patient identifiers, HCPCS/diagnosis codes, and provider TIN/NPI.
    SourceLink
    On This Page
    Medications and Coverage Rules Requiring Prior Authorization or NotificationBilling Codes and NDC Billing RequirementsHow Providers Must Request Prior Authorization and Operational NotesSymbols, Terms, and Key Definitions

    Prior authorization requirements (fragment)

    Medications listed require prior authorization or notification as indicated; providers must use Humana fax forms or electronic tools and comply with coding/NDC requirements.

    Providers must submit prior authorization or notification requests using Humana's specified fax forms or approved electronic processes (e.g., CoverMyMeds) where applicable.
    Requests should include required information such as patient identifiers, service date/location, HCPCS and diagnosis codes (up to 6), TIN/NPI for facility and performing provider, caller information, and relevant clinical documentation.
    All shared HCPCS codes and not‑otherwise‑classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims (‡ annotation).
    Certain products (e.g., CAR‑T, transplant‑related items, specialty biologics) are routed to specific review channels and may require submission to the Humana National Transplant Network when annotated (††).

    PA listing (excerpt)

    Excerpted listing notes — each medication entry includes the generic name and associated billing code(s); follow the referenced fax form to request prior authorization or provide notification.

    Medication entries list generic medication name and billing code(s); providers must access the corresponding PA/notification fax form to submit a request or provide notification.
    Entries annotated with ‡ indicate shared HCPCS or NOC codes that require an NDC on claims.
    Entries annotated with †† indicate preauthorization requests that will be reviewed by the Humana National Transplant Network with fax/phone/email submission options.

    Drugs requiring prior authorization/notification (partial list shown)

    Partial extract — listed drugs require prior authorization or notification; each entry provides the generic medication name and billing code(s).

    ANY of the following

    • Myobloc (rimabotulinumtoxinB) — Billing Code = J0587
    • Neulasta / Neulasta Onpro (pegfilgrastim) — Billing Code = J2506 (‡)
    • Onivyde (liposome injection) — Billing Code = J9205

    Medication prior authorization entries

    Medication prior authorization entries — each entry shows the generic name, example billing code(s), and any special flags (e.g., *, **, ‡, ††).

    Romidepsin — Billing Code = J9318; prior authorization/notification required.
    Ruconest — Generic: C1 esterase inhibitor; Billing Code = J0596; may carry new‑requirement (*) and step‑therapy (**) flags.
    Ruxience (rituximab‑pvvr) — Billing Code = Q5119; prior authorization/notification required.
    Starjemza / Stelara IV / related ustekinumab products — Billing Codes include C9399, J3490, J3590, J3358; entries may include shared HCPCS (‡) and step therapy (**) annotations.

    Drug-specific prior authorization entries (partial segment)

    Drug‑specific prior authorization entries (partial segment) — each listed medication requires prior authorization or notification and shows billing codes; special markers indicate NDC billing, new requirements, or transplant routing.

    Vyxeos (daunorubicin/cytarabine) — Billing Code = J9153; access Humana fax form to request preauthorization or provide notification.
    Xenpozyme (olipudase alfa‑rpcp) — Billing Code = J0218; prior authorization/notification required.
    Xolair (omalizumab) — Billing Code = J2357; prior authorization/notification required.

    Blood‑clotting factor examples

    • Advate — Billing Code = J7192 (‡ shared HCPCS/NOC requires NDC on claims)
    • Adynovate — Billing Code = J7207

    Billing Codes and NDC Billing Requirements

    sample HCPCS/J-codes from medication listmixedCovered
    Q2055Billing code listed for idecabtagene vicleucel (Abecma)
    J9264Billing code listed for paclitaxel-nab (Abraxane)
    J3262Billing code listed for tocilizumab (Actemra IV)
    Examples of listed billing codes in fragmentmixed
    Q5152billing code listed for eculizumab-aeeb (Bkemv IV)
    C9399unclassified HCPCS code used for multiple drugs (e.g., Blenrep, Defitelio, Empaveli)
    J3490not otherwise classified drug code (listed with several agents)
    J9039blinatumomab (Blincyto)
    J9145daratumumab (Darzalex)
    J9358fam-trastuzumab deruxtecan-nxki (Enhertu)
    Sample HCPCS/J-codes in excerptHCPCS | mixed
    J1566Immune globulin (Gammagard variants)
    J1561Immune globulin (Gammaked, Gamunex-C)
    J1557Gammaplex
    J9301Obinutuzumab (Gazyva)
    J7326Sodium hyaluronate (Gel-One)
    J7328Sodium hyaluronate (Gelsyn-3)
    J7320Sodium hyaluronate (Genvisc 850)
    J0223Givlaari (givosiran)
    J0257Glassia (alpha 1-proteinase inhibitor)
    sample HCPCS/J codes from listHCPCS
    J0587rimabotulinumtoxinB
    J1458galsulfase (Naglazyme)
    J2506pegfilgrastim (Neulasta, Neulasta Onpro)
    J1442filgrastim (Neupogen)
    J0219avalglucosidase alfa-ngpt (Nexviazyme)
    additional HCPCS/J codesHCPCS
    J2350ocrelizumab (Ocrevus)
    J1568immune globulin (Octagam)
    J0224lumasiran (Oxlumo)
    J7312dexamethasone intravitreal implant (Ozurdex)
    Representative J-/Q-/C-codes in this segmentmixedCovered
    J9318romidepsin
    J0596C1 esterase inhibitor (Ruconest)
    Q5119rituximab-pvvr (Ruxience)
    J9061amivantamab-vmjw (Rybrevant IV)
    J9153daunorubicin/cytarabine (Vyxeos)
    Additional codes from T–S listingsmixedCovered
    J3358ustekinumab (Stelara IV / Ustekinumab IV)
    J1627granisetron (Sustol)
    J9273tisotumab vedotin-tftv (Tivdak)
    Representative J-codes from listingsHCPCS | CPTCovered
    J9153Vyxeos (daunorubicin/cytarabine)
    J0218Xenpozyme (olipudase alfa-rpcp)
    J0588Xeomin (incobotulinumtoxinA)
    Blood-clotting factor J-codesHCPCSCovered
    J7192Advate/related antihemophilic factor entries (multiple brands share codes)
    J7207Adynovate
    J7214Altuviiio
    HCPCS NDC billing requirement — All shared HCPCS and NOC codes require a corresponding NDC on claims
    RequirementAll shared HCPCS and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.
    ScopeApplies to all Humana MA HMO and HMO POS members where the PAL applies (Humana HMO D‑SNP Michigan list).
    RationaleEnsures accurate identification of the specific drug product when multiple products share HCPCS or NOC codes.
    Claiming impactProviders must include the NDC on claims for any drug billed with a shared HCPCS or NOC code to avoid claim processing issues or denials.
    ReferenceNoted in the PAL special annotations and Important notes sections (‡ annotation).
    NDC requirement for HCPCS/NOC — NDC required on all claims for shared HCPCS/NOC codes
    RequirementAll shared HCPCS and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.
    Annotation symbolMarked with the '‡' symbol in the PAL legend indicating the NDC billing requirement.
    Operational noteProviders should confirm the correct NDC for the product administered and include it on the claim form when billing a shared HCPCS/NOC code.
    Where listedIncluded in the submission notes and repeated across the PAL medication listing entries and legend.
    NDC requirement for shared HCPCS/NOC — Billing NDC required
    RequirementShared HCPCS codes and not otherwise classified (NOC) codes require a corresponding NDC to be billed on all claims.
    Legend usageThe '‡' marker next to drug entries denotes this billing requirement.
    Provider actionInclude the product NDC on the claim to identify the exact drug when billing a shared HCPCS or NOC code.
    ConsequenceFailure to include the NDC may lead to claim processing issues or requests for additional information.
    NDC billing requirement for shared HCPCS/NOC codes
    RequirementAll shared HCPCS and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.
    Document placementStated in the Important notes and reiterated in multiple 'How to request prior authorization' sections and legend entries throughout the PAL.
    NotationAppears as the '‡' flag beside affected medication entries in the PAL.
    Submission tipVerify and bill the exact NDC for the dispensed product when submitting claims for HCPCS/NOC-coded medications.

    How Providers Must Request Prior Authorization and Operational Notes

    Prior Authorization

    Methods to initiate prior authorization

    Prior authorization requests for medications may be initiated online via CoverMyMeds, by phone at 866-461-7273 (TTY: 711), Monday–Friday, 8 a.m.–11 p.m. Eastern time, or by fax to 888-447-3430. Request forms are available on Humana's prior authorization for professionally administered drugs website.

    • Online: CoverMyMeds
    • Phone: 866-461-7273 (TTY: 711), Mon–Fri 8 a.m.–11 p.m. ET
    • Fax: 888-447-3430 (use Humana PA fax forms)
    Documentation Required

    Information required for prior authorization requests

    Submit complete patient identifiers and service details with each prior authorization or notification request; include HCPCS and diagnosis codes, service date and location, provider and facility TIN/NPI, caller contact, and relevant clinical information to expedite determinations.

    • Patient name, date of birth, Humana member ID
    • Date of actual service or hospital admission
    • HCPCS code(s) and diagnosis codes (up to 6)
    • Service location (inpatient/outpatient/home/etc.)
    • TIN and NPI of facility and provider performing service
    • Caller/requester name and phone number and attending provider phone
    • Relevant clinical information
    Denial Risk

    Denial risk and delegated network note

    Failure to obtain required prior authorization may result in financial penalties to the practice, reduced patient benefits, and retrospective review; delegated IPAs and risk networks are subject to the PAL and should follow their network guidance.

    • Urgent/emergent services do not require prior authorization
    • Delegated IPA/risk network providers must follow PAL and their network guidance
    Prior Authorization

    Use fax forms for sample medication entries

    Access Humana's fax forms to request preauthorization or provide notification for listed medications; examples in the list include eculizumab-aeeb (Bkemv IV, Q5152), belantamab mafodotin-blmf (Blenrep, C9399/J3490/J3590/J9999), blinatumomab (Blincyto, J9039), denosumab-bnht (Bomyntra, Q5158), and bortezomib (J9046).

    • Example entries: Bkemv IV (eculizumab-aeeb) — Q5152
    • Blenrep (belantamab mafodotin-blmf) — C9399, J3490, J3590, J9999
    • Blincyto (blinatumomab) — J9039
    • Bomyntra (denosumab-bnht) — Q5158
    • bortezomib — J9046
    Prior Authorization

    CAR‑T and specialty therapy prior authorization via fax forms

    CAR-T and other specialty therapies listed (marked ††) require prior authorization and should be submitted using the listed fax forms; examples include Carvykti (ciltacabtagene autoleucel, Q2056) and Casgevy (exagamglogene autotemcel, J3392).

    • Carvykti (ciltacabtagene autoleucel) — Q2056 (††)
    • Casgevy (exagamglogene autotemcel) — J3392 (††)
    Documentation Required

    Submission notes and special program annotations

    Submission annotations and program notes: * = new preauthorization requirement; † = new-to-market drug; ‡ = shared HCPCS/NOC codes require a corresponding NDC on all claims; ** = step therapy required through a Humana-preferred drug as part of preauthorization; †† = transplant-reviewed items are routed to the Humana National Transplant Network.

    • * New preauthorization requirement
    • † New-to-market drug addition
    • ‡ Shared HCPCS/NOC codes require NDC on claims
    • ** Step therapy required through a Humana-preferred drug
    • †† Transplant items reviewed by Humana National Transplant Network
    Prior Authorization

    Medication listings and PA requirement examples

    Providers must request prior authorization for the drugs listed in the PAL; entries include generic medication name and billing codes (examples: immune globulin products J1566/J1569/J1561, Gammaplex J1557, Gazyva J9301, Gel‑One J7326).

    • Immune globulin — J1566, J1569, J1561
    • Gammaplex — J1557
    • Gazyva (obinutuzumab) — J9301
    • Gel‑One (sodium hyaluronate) — J7326
    Documentation Required

    Annotations and PA submission notes

    Legend and submission implications: entries flagged with symbols require special submission handling (e.g., ‡ entries require NDC billing on claims; ** entries may require step therapy documentation). Providers should follow the legend when preparing PA requests.

    • ‡ — include corresponding NDC on claims for shared HCPCS/NOC codes
    • ** — step therapy may be required; document trials of preferred drugs
    • * / † — indicate new PA requirement or new-to-market additions
    Prior Authorization

    Transplant and fax form instructions

    For transplant-related and other complex therapies (††), access the Humana fax forms to request preauthorization or provide notification; the Humana National Transplant Network reviews these requests and provides dedicated contact channels.

    • Use Humana PA fax forms for transplant-related items
    • Humana National Transplant Network handles †† items
    Billing Rule

    General PA billing and step therapy requirements

    All shared HCPCS codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on claims; step therapy may be required for some drugs and new PA requirements are indicated in the list.

    • ‡ — NDC must be billed on all claims for shared HCPCS/NOC codes
    • ** — step therapy may apply through Humana‑preferred drugs
    Prior Authorization

    Transplant preauthorization submission instructions

    Transplant preauthorization requests are reviewed by the Humana National Transplant Network and may be submitted by fax to 502-508-9300, by phone at 866-421-5663 (Mon–Fri 7 a.m.–7 p.m. CT), or by email to transplant@humana.com.

    • Fax: 502-508-9300
    • Phone: 866-421-5663, Mon–Fri 7 a.m.–7 p.m. CT
    • Email: transplant@humana.com
    Prior Authorization

    How to request prior authorization for listed drugs

    Use Humana's fax forms to request prior authorization or provide notification for each listed drug; every drug entry in the list includes the generic medication name and its associated billing code(s) to include on the request.

    • Include the drug's generic name and billing code(s) on the PA request
    • Access the specific fax form referenced in the PAL for that drug
    Prior Authorization

    Medication prior authorization entries (sample)

    Sample medication entries shown in the PAL list require prior authorization or notification and include billing codes; examples include romidepsin (J9318), Ruconest (C1 esterase inhibitor, J0596), Ruxience (rituximab-pvvr, Q5119), and Rybrevant IV (J9061).

    • romidepsin — J9318
    • Ruconest (C1 esterase inhibitor) — J0596
    • Ruxience (rituximab-pvvr) — Q5119
    • Rybrevant IV (amivantamab-vmjw) — J9061
    Note

    Legend and special routing

    The PAL legend explains the routing and special markers: * = new PA requirement; † = new-to-market drug; ‡ = shared HCPCS/NOC codes require NDC; ** = step therapy required; †† = transplant-reviewed with Humana National Transplant Network contact details.

    • * new preauthorization requirement
    • † new‑to‑market drug addition
    • ‡ NDC required for shared HCPCS/NOC codes
    • ** step therapy required through a Humana‑preferred drug
    • †† transplant review routing
    Prior Authorization

    Transplant preauthorization contact and routing

    Humana National Transplant Network contact for †† items: fax 502-508-9300; phone 866-421-5663 (Mon–Fri 7 a.m.–7 p.m. CT); email transplant@humana.com. Use these channels for transplant-related preauthorization submissions.

    • Fax: 502-508-9300
    • Phone: 866-421-5663, Mon–Fri 7 a.m.–7 p.m. CT
    • Email: transplant@humana.com
    Documentation Required

    Prior authorization request instructions and special notes

    Prior authorization requests must reflect any new PA requirements or step therapy expectations noted in the PAL; providers should include step therapy documentation when an entry is marked with ** and ensure shared HCPCS/NOC codes include the corresponding NDC on claims.

    • Document prior trials of Humana‑preferred drugs for ** (step therapy) items
    • Include NDC on claims for ‡ (shared HCPCS/NOC) items
    Prior Authorization

    Vyxeos (J9153) prior authorization example

    Drug‑specific example: Vyxeos (daunorubicin/cytarabine) requires prior authorization; include billing code J9153 on the request and use Humana's fax form to submit the preauthorization or notification.

    • Vyxeos (daunorubicin/cytarabine) — J9153
    • Submit via Humana PA fax form to request preauthorization or provide notification
    Prior Authorization

    Zynyz (J9345) prior authorization example

    Drug‑specific example: Zynyz (retifanlimab-dlwr) requires prior authorization; include billing code J9345 and submit using the appropriate Humana fax form to request preauthorization or provide notification.

    • Zynyz (retifanlimab-dlwr) — J9345
    • Use Humana PA fax form to request preauthorization or provide notification

    Symbols, Terms, and Key Definitions

    Prior authorization — Definition of prior authorization / precertification
    DefinitionPrior authorization (also preauthorization, precertification) — a process through which the healthcare provider is required to obtain advance approval from the plan as to whether an item or service will be covered.
    When requiredRequired for medications delivered in-office, clinic, outpatient, or home settings listed on the PAL prior to being provided or administered.
    ExceptionsUrgent/emergent services do not require prior authorization; investigational/experimental procedures usually are not covered.
    How to confirmConsult the patient's Evidence of Coverage or Humana for confirmation of coverage.
    Step therapy — Definition and cross‑benefit application
    DefinitionStep therapy — a requirement to try a Humana‑preferred drug before coverage of a non‑preferred medication; strategies may span Medicare Part B and Part D benefits.
    Cross‑benefit noteSome step therapy strategies may require trials across Part B and Part D; refer to Humana's Part B Step Therapy PDL for details.
    Impact on PAStep therapy may be enforced as part of the preauthorization process and is indicated with '**' in the PAL legend.
    Provider optionIf providers do not stock a preferred medication, they may obtain it from a pharmacy (specialty or mail-order) that can ship to the office.
    Step therapy marker (legend entry)
    Legend marker**
    MeaningIndicates step therapy on the PAL (trial of a Humana‑preferred drug required).
    PlacementAppears next to medication entries that require step therapy in the listing.
    New‑to‑market drug addition (legend entry)
    Legend marker†
    MeaningDenotes a new‑to‑market drug addition on the PAL.
    PlacementAppears next to medication entries that are new‑to‑market additions.
    HCPCS/NOC billing NDC requirement (legend entry)
    Legend marker‡
    MeaningShared HCPCS and not otherwise classified (NOC) codes require a corresponding NDC to be billed on all claims.
    UsagePlaced next to affected medication entries and listed in the PAL legend and Important notes.
    Transplant preauthorization review (legend entry)
    Legend marker††
    MeaningIndicates preauthorization requests are reviewed by the Humana National Transplant Network.
    Submission channelsTransplant requests can be submitted by fax to 502‑508‑9300, by phone at 866‑421‑5663 (Mon–Fri 7 a.m.–7 p.m. CT), or by email to transplant@humana.com.
    Symbol legend / submission notes — Expanded legend mapping for *, **, †, ‡, ††
    Symbols* = New preauthorization requirement; ** = Step therapy required through a Humana‑preferred drug as part of preauthorization; † = New‑to‑market drug addition; ‡ = Shared HCPCS/NOC codes require corresponding NDC on claims; †† = Preauthorization requests reviewed by Humana National Transplant Network (fax/phone/email provided).
    Where listedLegend appears in the Important notes and repeated in the 'How to request prior authorization' sections throughout the PAL.
    Action for providersCheck legend flags on each medication entry to determine special billing or submission requirements before submitting a PA or claim.
    HCPCS shared/NOC code billing requirement — Restatement of NDC requirement for shared HCPCS/NOC codes
    Requirement restatedAll shared HCPCS and not otherwise classified codes require a corresponding NDC to be billed on all claims (‡).
    PlacementStated in general prior authorization notes and emphasized in the PAL legend and listing entries.
    Provider responsibilityInclude the NDC when submitting claims for medications billed with shared HCPCS/NOC codes.
    Step therapy marker — '**' indicates step therapy required through a Humana‑preferred drug as part of preauthorization
    Marker meaning** indicates step therapy is required through a Humana‑preferred drug as part of preauthorization.
    Where to find detailsRefer to Humana's Medicare Part B Step Therapy PDL for program details and preferred drug lists.
    PA implicationPA requests may be contingent on completion of required step‑therapy trials per the PDL and coverage policies.
    Transplant review marker — '††' indicates Humana National Transplant Network review
    Marker meaning†† indicates preauthorization requests are reviewed by the Humana National Transplant Network.
    Submission channelsRequests for †† items can be submitted via fax (502‑508‑9300), phone (866‑421‑5663, Mon–Fri 7 a.m.–7 p.m. CT), or email (transplant@humana.com).
    ContextUsed for transplant‑related therapies and other complex products requiring specialized review.
    †† (transplant review routing) — Submission channels for transplant review
    ProcessTransplant preauthorization requests reviewed by the Humana National Transplant Network can be submitted by fax, phone, or email.
    Fax502‑508‑9300
    Phone866‑421‑5663 (Mon–Fri 7 a.m.–7 p.m. CT)
    Emailtransplant@humana.com
    ‡ (shared HCPCS/NOC code NDC requirement) — NDC requirement reiterated
    RequirementShared HCPCS and not otherwise classified (NOC) codes require a corresponding NDC to be billed on all claims (‡).
    LegendDenoted with '‡' in the PAL legend and next to applicable medication entries.
    Provider actionVerify and include the NDC on claims when billing shared HCPCS/NOC codes to ensure accurate product identification.
    ** (step therapy) — Step therapy required through a Humana‑preferred drug as part of preauthorization
    Definition** indicates step therapy required through a Humana‑preferred drug as part of the preauthorization process.
    ReferenceSee Humana's Part B Step Therapy PDL and PAL entries for affected medications and required trials.
    Provider guidanceReview the Step Therapy PDL to determine required preferred agents and acceptable trial evidence when submitting PA requests.
    *, † (new requirement / new‑to‑market) — Legend entries for '*' and '†' markers
    '*' meaning* indicates a new preauthorization requirement for the medication.
    '†' meaning† indicates the medication is a new‑to‑market drug addition.
    Where shownThese markers appear next to medication entries in the PAL and are explained in the legend.
    Step therapy enforcement — Additional step therapy definition/reference
    DefinitionStep therapy requires attempting a Humana‑preferred drug before coverage of a non‑preferred medication and may be enforced during preauthorization.
    ReferenceHumana's Part B Step Therapy PDL provides program details and cross‑benefit considerations.
    Notation on PALMedications subject to step therapy are flagged with '**' in the PAL listings.
    Transplant preauthorization review — National Transplant Network review instructions
    PolicyPreauthorization requests for transplant‑related therapies will be reviewed by the Humana National Transplant Network.
    Submission optionsFax: 502‑508‑9300; Phone: 866‑421‑5663 (Mon–Fri 7 a.m.–7 p.m. CT); Email: transplant@humana.com.
    ScopeApplies to items marked with '††' in the PAL, typically transplant‑related or complex therapies.